Radiofrequency ablation in Barrett's esophagus with dysplasia.

  title={Radiofrequency ablation in Barrett's esophagus with dysplasia.},
  author={Nicholas J. Shaheen and Prateek Sharma and Bergein F. Overholt and Herbert C. Wolfsen and Richard E. Sampliner and Kenneth K Wang and Joseph A. Galanko and Mary P. Bronner and John R. Goldblum and Ana E. Bennett and Blair A Jobe and Glenn M. Eisen and M. Brian Fennerty and John G. Hunter and David E. Fleischer and Virender Kumar Sharma and Robert Holbrook Hawes and Brenda J. Hoffman and Richard I. Rothstein and Stuart R. Gordon and Hiroshi Mashimo and Kenneth J. Chang and V. Raman Muthusamy and Steven A. Edmundowicz and Stuart Jon Spechler and Ali A Siddiqui and Rhonda F. Souza and Anthony Infantolino and Gary W. Falk and Michael B. Kimmey and Ryan D. Madanick and Amitabh Chak and Charles J. Lightdale},
  journal={The New England journal of medicine},
  volume={360 22},
BACKGROUND Barrett's esophagus, a condition of intestinal metaplasia of the esophagus, is associated with an increased risk of esophageal adenocarcinoma. We assessed whether endoscopic radiofrequency ablation could eradicate dysplastic Barrett's esophagus and decrease the rate of neoplastic progression. METHODS In a multicenter, sham-controlled trial, we randomly assigned 127 patients with dysplastic Barrett's esophagus in a 2:1 ratio to receive either radiofrequency ablation (ablation group… 

Figures and Tables from this paper

Outcomes of Radiofrequency Ablation for Dysplastic Barrett's Esophagus: A Comprehensive Review

Treatment of dysplastic Barrett's esophagus with radiofrequency ablation results in complete eradication of both dysplasia and of intestinal metaplasia in a high proportion of patients with a low incidence of adverse events.

Radiofrequency Ablation for Dysplastic Barrett’s Esophagus

Radiofrequency ablative therapy has now become the standard of care for high-grade dysplasia as opposed to observation alone, esophagectomy, or photodynamic therapy and it is recommended that patients have two endoscopies in high definition with biopsies and within 2 months prior to undergoing ablation.

Barrett esophagus: Complete eradication of dysplasia

Radiofrequency ablation was associated with high rates of complete eradication of dysplasia and intestinal metaplasia, and decreased disease progression, compared with the sham procedure, and the authors believe that the use of radio frequencies ablation is worth considering for patients with low-grade Dysplasia.

Endoscopic radiofrequency ablation therapy for the prevention of esophageal cancer in Barrett’s esophagus

Radiofrequency ablation achieves complete eradication of (non) dysplastic Barrett's esophagus in most individuals, and the risk of progression to higher grades of dysplasia or cancer is reduced after RFA, although not completely eliminated.

Editorial: Endpoints for Radiofrequency Ablation in Barrett's Dysplasia

Radiofrequency ablation has been shown to be a safe and effective endoscopic treatment modality for dysplastic BE and complete eradication of dysplasia or intestinal metaplasia was determined after a single post-RFA endoscopic examination with biopsies.

Length of Barrett’s segment predicts failure of eradication in radiofrequency ablation for Barrett’s esophagus: a retrospective cohort study

Length of Barrett’s segment > 5 cm was found to be predictive of failure of eradication in patients undergoing radiofrequency ablation, associated with a high rate of complete eradication.

Barrett’s Esophagus: Radiofrequency (RF) and Other Ablation Modalities

In 2009, endoscopic radiofrequency mucosal ablation for Barrett’s with high-grade dysplasia was proven effective, introducing the world to a well-tolerated, reproducible, and safe technology that ushered in the modern era of endoscopic treatment of dysplastic BE.

Intestinal Metaplasia Recurs Infrequently in Patients Successfully Treated for Barrett's Esophagus With Radiofrequency Ablation

In patients with BE and dysplasia or early cancer who achieved CE-IM, BE recurred in ∼5%/year, and subjects undergoing RFA for dysplastic BE should be retained in endoscopic surveillance.



Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia.

HGD without cancer in Barrett's esophagus follows a relatively benign course in the majority of patients, and in the patients who eventually progress to cancer during regular surveillance, surgical resection is curative.

The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the cleveland clinic barrett's esophagus registry

The study suggests that the incidence of adenocarcinoma in Barrett's esophagus is lower than initially thought, however, large multicenter studies are required to clarify the epidemiological and clinical factors related to the development of dysplasia and adenOCarcin cancer in patients followed prospectively.

Prevalence of Barrett's esophagus in the general population: an endoscopic study.

Alcohol and smoking were significant risk factors for the prevalence of Barrett's esophagus in an adult Swedish population and the prevalence in the general population was found to be 1.6% of the general Swedish population.

The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years.

The current series is larger and has a longer follow-up period than previous prospective trials and demonstrates a lower incidence of adenocarcinoma.

The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years.

A larger and has a longer follow-up period than previous prospective trials and demonstrates a lower incidence of adenocarcinoma in patients with Barrett's esophagus.

Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus

The guidelines for the diagnosis, surveillance and therapy of Barrett’s esophagus were originally published by the American College of Gastroenterology in 1998 and updated in 2002 and once again reviewed using the National Library of Medicine database.

Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma.

Patients with focal HGD are less likely to have cancer during the first year after diagnosis or on subsequent follow-up compared with diffuse HGD.